Dermapharm Holding Se · XETR:DMP

Dermapharm — H1 2021 Earnings Presentation

17 slides from Dermapharm's earnings presentation, Sep 7, 2021

  1. Slide 1: Investors' and Analysts' Conference Call H1 2021

    INVESTORS’ AND ANALYSTS’ CONFERENCE CALL H1 2021 Grünwald, 7 September 2021

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights H1 2021 2. Financial figures H1 2021 3. Outlook FY 2021 4. Q & A

  4. Slide 4: Agenda: Highlights H1 2021

    AGENDA 1. Highlights H1 2021 2. Financial figures H1 2021 3. Outlook FY 2021 4. Q & A

  5. Slide 5: Highlights H1 2021: Dermapharm with accelerated growth in first half-year 2021

    Highlights H1 2021 Dermapharm with accelerated growth in first half-year 2021 Vaccine production Ongoing vaccine production in Brehna and Reinbek – groundwork is being laid for optimised “fill & finish” process in Brehna CORAT Therapeutics Development of an antibody drug (COR-101) for hospitalised C

  6. Slide 6: Agenda: Financial figures H1 2021

    AGENDA 1. Highlights H1 2021 2. Financial figures H1 2021 3. Outlook FY 2021 4. Q & A

  7. Slide 7: Dermapharm Group: Excellent growth, while COVID-19 pandemic slowed down

    Dermapharm Group Excellent growth, while COVID-19 pandemic slowed down Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA margin +13.1% YoY 24.2% 32.0% 427.7 Significant revenue growth of 13.1% to €427.7m, due to 378.2  revenue contribution of acquisition Allergopharma, not considered in Q

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Strong growth contribution from Allergopharma, vaccine and vitamines Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +27.9% YoY 37.6% 47.8% Revenues up by 27.9% to €271.2m  full H1 period contribution of Allergopharma  strong growt

  9. Slide 9: Herbal extracts

    Herbal extracts Recovery of global markets for herbal extracts Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin -0.3% YoY 23.9% 25.1% Revenues decreased by 0.3% to €39.3m, comprising Euromed  ongoing recovery of global demand led to higher sales volume  negative impact on revenues due

  10. Slide 10: Parallel import business

    Parallel import business Declining market and regulatory changes impact results Revenue (€m) EBITDA (€m) Comments EBITDA Margin -7.5% YoY 4.1% 0.8% Revenues decreased by 7.5% to €117.2m  declining demand in the entire PI market  growth in direct traded OTC, narcotics and medical 117.2 cannabis cou

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to M&A and business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 15.5% 25.4%  EBT increased by 85.2% to €108.7m (unadjusted) resulting in a margin of 25.4% Mainly influenced by +85.2% YoY  disproportional increase of depreciation

  12. Slide 12: Strong operating cash flows and cash conversion

    Strong operating cash flows and cash conversion Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 44.6% 54.1%  CF from operating activities increased, mainly influenced by increased EBT in H1 2021  CF from investing activities decreased in H1 2021  Less investing

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 30 June 2021 (€m) Comments  Total assets increased to €1,278m (31 December 2020: €1,224m) 1,278 1,278  Non-current assets increased to €851m (31 December 2020: €824m)  Current assets increased to €427m (31 December 2020: €400m), mainly due to

  14. Slide 14: Agenda: Outlook FY 2021

    AGENDA 1. Highlights H1 2021 2. Financial figures H1 2021 3. Outlook FY 2021 4. Q & A

  15. Slide 15: Growth strategy on track - conforming guidance 2021

    Growth strategy on track - conforming guidance 2021 positive growth of 24 - 26% Revenues 2021 vs. previous year (€793.8m) EBITDA 2021 positive growth of 45 - 50% (adjusted) vs. previous year (€200.7m) Based on the H1 development we confirm the guidance given for 2021. Impact of effects resulting fro

  16. Slide 16: Agenda: Q & A

    AGENDA 1. Highlights H1 2021 2. Financial figures H1 2021 3. Outlook FY 2021 4. Q & A

  17. Slide 17: Investor contact

    Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — H1 2021 Earnings Presentation on 6ix